Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
GLP-1 Market: Key Segments Currently, Small Molecule Segment Occupies the Largest Share of the GLP-1 Market In terms of type of molecule, the market is segmented into biologics and small molecules
[62] Viking Therapeutics (VK2735) VK2735 is a GLP1R/GIPR dual agonist, with a half-life of around 170-250 hours, undergoing both oral and subcutaneous injection clinical trials
Individual Variability : Each person may respond differently to peptide therapy
Nausea and Vomiting: Common side effects include severe nausea, vomiting, and facial flushing
US$ 26.76
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 22.96
US$ 25.68
US$ 27.77
US$ 24.20
US$ 23.00
